A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

Drug repurposing is the only method capable of delivering treatments on the shortened time-scale required for patients afflicted with lung disease arising from SARS-CoV-2 infection. Mucin-1 (MUC1), a membrane-bound molecule expressed on the apical surfaces of most mucosal epithelial cells, is a bioc...

Descripción completa

Detalles Bibliográficos
Autores principales: Alimova, Maria, Sidhom, Eriene-Heidi, Satyam, Abhigyan, Dvela-Levitt, Moran, Melanson, Michelle, Chamberlain, Brian T., Alper, Seth L., Santos, Jean, Gutierrez, Juan, Subramanian, Ayshwarya, Grinkevich, Elizabeth, Bricio, Estefania Reyes, Kim, Choah, Clark, Abbe, Watts, Andrew, Thompson, Rebecca, Marshall, Jamie, Pablo, Juan Lorenzo, Coraor, Juliana, Roignot, Julie, Vernon, Katherine A., Keller, Keith, Campbell, Alissa, Emani, Maheswarareddy, Racette, Matthew, Bazua-Valenti, Silvana, Padovano, Valeria, Weins, Astrid, McAdoo, Stephen P., Tam, Frederick W.K., Ronco, Lucienne, Wagner, Florence, Tsokos, George C., Shaw, Jillian L., Greka, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337390/
https://www.ncbi.nlm.nih.gov/pubmed/32637960
http://dx.doi.org/10.1101/2020.06.30.180380

Ejemplares similares

Ejemplares similares